Technical Analysis for HTBX - Heat Biologics, Inc.

Grade Last Price % Change Price Change
F 5.95 2.94% 0.17
HTBX closed up 2.94 percent on Friday, May 14, 2021, on 64 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical HTBX trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Below Lower BB Weakness 2.94%
Down 3 Days in a Row Weakness 2.94%
Lower Bollinger Band Touch Weakness 2.94%
Oversold Stochastic Weakness 2.94%
NR7 Range Contraction -1.65%
Older End-of-Day Signals for HTBX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 2 days ago
Up 3% 2 days ago
Possible Inside Day 2 days ago
Possible NR7 2 days ago
Up 2% 2 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Heat Biologics, Inc. Description

Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Non Small Cell Lung Cancer Ovarian Cancer Vaccine Vaccination Cancer Treatment HIV Platform Technology Bladder Cancer Treatment Of Non Small Cell Lung Cancer Cancer Vaccine Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge

Is HTBX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 30.1
52 Week Low 4.34
Average Volume 476,203
200-Day Moving Average 8.15
50-Day Moving Average 7.26
20-Day Moving Average 6.58
10-Day Moving Average 6.36
Average True Range 0.43
ADX 20.16
+DI 11.61
-DI 27.25
Chandelier Exit (Long, 3 ATRs ) 6.10
Chandelier Exit (Short, 3 ATRs ) 6.97
Upper Bollinger Band 7.42
Lower Bollinger Band 5.74
Percent B (%b) 0.12
BandWidth 25.52
MACD Line -0.34
MACD Signal Line -0.28
MACD Histogram -0.0617
Fundamentals Value
Market Cap 951.08 Million
Num Shares 160 Million
EPS -0.65
Price-to-Earnings (P/E) Ratio -9.10
Price-to-Sales 21.18
Price-to-Book 1.50
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.24
Resistance 3 (R3) 6.21 6.10 6.19
Resistance 2 (R2) 6.10 6.02 6.11 6.17
Resistance 1 (R1) 6.02 5.98 6.06 6.05 6.16
Pivot Point 5.91 5.91 5.93 5.92 5.91
Support 1 (S1) 5.83 5.83 5.87 5.86 5.74
Support 2 (S2) 5.72 5.79 5.73 5.73
Support 3 (S3) 5.64 5.72 5.71
Support 4 (S4) 5.67